Patents to new medicines usually protect the active ingredient (compound), provided that it is new and inventive. It is also a common … “Brazil: The patent combination conundrum” for LSIPR Magazine
Kasznar Leonardos’ Marketing & Entertainment Law practice group is pleased to publish its first Advertising Law Year in Review newsletter highlighting the … Advertising Law | Year In Review | 2022
When Facebook CEO and one of the planet’s wealthiest, Mark Zuckerberg, changed his company’s name to Meta in October 2021, he simultaneously … Digital influencers and advertising in the Metaverse and social media
Our partner Priscila Kashiwabara and specialists Breno Alves and Gabriel Cavalcante published the article “Sustainable agriculture, green technologies and IP in Brazil” in the Global Patent Prosecution Guide … Sustainable agriculture, green technologies and IP in Brazil
Our partner Claudio Barbosa and our Attorney at Law Viviane Trojan are the authors of the article “Brazil: Patent Litigation”, published in the Global Patent … Brazil: Patent Litigation 2023 – IAM Media
Our partner and head of Life Sciences, Priscila Kashiwabara discusses plant variety protection in Brazil and its recent developments regarding legal framework for Plant … Protecting Plant Varieties in Brazil for FloraCulture Magazine
Patents are critical to the life sciences industry and often spark intense and heated debate. To be successful, one key strategy that … Life sciences patent eligibility in Latin America: a guide
Our partners Claudio Barbosa and Rafael Lacaz Amaral authored a chapter about Brazil, first appeared in Global Patent Litigation Guide: Helping businesses navigate … Global Patent Litigation 2022 – Brazil
The Q&A guide gives a high-level overview of privacy rules and principles, including what national laws regulate the right to respect for … Privacy in Brazil 2021
Our partners Anderson Ribeiro, Aline Ferreira and Priscila Kashiwabara authored the chapter "Personalised medicine in Brazil: IP and regulatory challenges". This article first … Personalised medicine in Brazil: IP and regulatory challenges
